Stockreport

MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake’s SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority

MoonLake Immunotherapeutics - Class A Ordinary Shares  (MLTX) 
PDF SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Global plaintiffs’ rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment [Read more]